Wolfgang Otto

List of Publications by Year
in descending order

53 papers	1,226 citations	430442 18 h-index	414034 32 g-index
53 all docs	53 docs citations	53 times ranked	1781 citing authors

#	Article	IF	Citations
1	The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes. Cancer Immunology Research, 2019, 7, 923-938.	1.6	148
2	The WHO classification of 1973 is more suitable than the WHO classification of 2004 for predicting survival in pT1 urothelial bladder cancer. BJU International, 2011, 107, 404-408.	1.3	86
3	Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. European Journal of Cancer, 2019, 106, 234-243.	1.3	75
4	Analysis of Sex Differences in Cancer-Specific Survival and Perioperative Mortality Following Radical Cystectomy: Results of a Large German Multicenter Study of Nearly 2500 Patients with Urothelial Carcinoma of the Bladder. Gender Medicine, 2012, 9, 481-489.	1.4	65
5	In stage pT1 non-muscle-invasive bladder cancer (NMIBC), high KRT20 and low KRT5 mRNA expression identify the luminal subtype and predict recurrence and survival. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2017, 470, 267-274.	1.4	58
6	FGFR3 Mutation Status and FGFR3 Expression in a Large Bladder Cancer Cohort Treated by Radical Cystectomy: Implications for Anti-FGFR3 Treatment?â€. European Urology, 2020, 78, 682-687.	0.9	57
7	High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients. Cancer Immunology, Immunotherapy, 2018, 67, 403-412.	2.0	54
8	Cytotoxic T-cell-related gene expression signature predicts improved survival in muscle-invasive urothelial bladder cancer patients after radical cystectomy and adjuvant chemotherapy. , 2020, 8, e000162.		45
9	Biochemical Foundations of Health and Energy Conservation in Hibernating Free-ranging Subadult Brown Bear Ursus arctos. Journal of Biological Chemistry, 2016, 291, 22509-22523.	1.6	37
10	Epithelialâ€"mesenchymal transformation markers E-cadherin and survivin predict progression of stage pTa urothelial bladder carcinoma. World Journal of Urology, 2016, 34, 709-716.	1.2	36
11	mRNA-Expression of KRT5 and KRT20 Defines Distinct Prognostic Subgroups of Muscle-Invasive Urothelial Bladder Cancer Correlating with Histological Variants. International Journal of Molecular Sciences, 2018, 19, 3396.	1.8	35
12	A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy. Oncotarget, 2018, 9, 15001-15014.	0.8	33
13	CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making. Scientific Reports, 2018, 8, 14383.	1.6	32
14	ESR1, ERBB2, and Ki67 mRNA expression predicts stage and grade of non-muscle-invasive bladder carcinoma (NMIBC). Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 469, 547-552.	1.4	25
15	The World Health Organization 1973 classification system for grade is an important prognosticator in T1 nonâ€muscleâ€invasive bladder cancer. BJU International, 2018, 122, 978-985.	1.3	25
16	High proliferation rate and TNM stage but not histomorphological subtype are independent prognostic markers for overall survival in papillary renal cell carcinoma. Human Pathology, 2019, 83, 212-223.	1.1	23
17	High Androgen Receptor mRNA Expression Is Independently Associated with Prolonged Cancer-Specific and Recurrence-Free Survival in Stage T1 Bladder Cancer. Translational Oncology, 2017, 10, 340-345.	1.7	22
18	Prognostic markers in invasive bladder cancer: FGFR3 mutation status versus P53 and KI-67 expression: a multi-center, multi-laboratory analysis in 1058 radical cystectomy patients. Urologic Oncology: Seminars and Original Investigations, 2022, 40, 110.e1-110.e9.	0.8	22

#	Article	IF	Citations
19	No mutations of FGFR3 in normal urothelium in the vicinity of urothelial carcinoma of the bladder harbouring activating FGFR3 mutations in patients with bladder cancer. International Journal of Cancer, 2009, 125, 2205-2208.	2.3	20
20	Metric substage according to micro and extensive lamina propria invasion improves prognostics in T1 bladder cancer. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 361.e7-361.e13.	0.8	20
21	<scp>FOXM</scp>1 overexpression is associated with adverse outcome and predicts response to intravesical instillation therapy in stage <scp>pT</scp>1 non‐muscle‐invasive bladder cancer. BJU International, 2019, 123, 187-196.	1.3	19
22	Comparative analysis of comorbidity and performance indices for prediction of oncological outcomes in patients with upper tract urothelial carcinoma who were treated with radical nephroureterectomy. Urologic Oncology: Seminars and Original Investigations, 2014, 32, 1141-1150.	0.8	18
23	Infiltrative lamina propria invasion pattern as an independent predictor for cancer‐specific and overall survival of instillation treatment‐naïve stageÂT1 high‐grade urothelial bladder cancer. International Journal of Urology, 2018, 25, 442-449.	0.5	17
24	Differentiation‐associated urothelial cytochrome P450 oxidoreductase predicates the xenobiotic‐metabolizing activity of "luminal‐muscle‐invasive bladder cancers. Molecular Carcinogenesis, 2018, 57, 606-618.	1.3	17
25	Expression, localisation and potential significance of aquaporins in benign and malignant human prostate tissue. BMC Urology, 2018, 18, 75.	0.6	17
26	High CDKN2A/p16 and Low FGFR3 Expression Predict Progressive Potential of Stage pT1 Urothelial Bladder Carcinoma. Clinical Genitourinary Cancer, 2018, 16, 248-256.e2.	0.9	16
27	Androgen Receptor mRNA Expression in Urothelial Carcinoma of the Bladder: A Retrospective Analysis of Two Independent Cohorts. Translational Oncology, 2019, 12, 661-668.	1.7	16
28	FOXM1 predicts overall and disease specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypes. Oncotarget, 2017, 8, 47595-47606.	0.8	16
29	Predictive value of molecular subtyping in NMIBC by RT-qPCR of ERBB2, ESR1, PGR and MKI67 from formalin fixed TUR biopsies. Oncotarget, 2017, 8, 67684-67695.	0.8	16
30	Photodynamic Diagnosis for Superficial Bladder Cancer: Do All Risk-Groups Profit Equally from Oncological and Economic Long-Term Results?. Clinical Medicine Oncology, 2009, 3, CMO.S1012.	0.2	14
31	High Stroma T-Cell Infiltration is Associated with Better Survival in Stage pT1 Bladder Cancer. International Journal of Molecular Sciences, 2020, 21, 8407.	1.8	14
32	FOXA1 Gene Expression for Defining Molecular Subtypes of Muscle-Invasive Bladder Cancer after Radical Cystectomy. Journal of Clinical Medicine, 2020, 9, 994.	1.0	14
33	Loss of AQP3 protein expression is associated with worse progression-free and cancer-specific survival in patients with muscle-invasive bladder cancer. World Journal of Urology, 2015, 33, 1959-1964.	1.2	12
34	WHO 1973 grade 3 and infiltrative growth pattern proved, aberrant E-cadherin expression tends to be of predictive value for progression in a series of stage T1 high-grade bladder cancer after organ-sparing approach. International Urology and Nephrology, 2017, 49, 431-437.	0.6	11
35	A switch from epithelial to mesenchymal properties correlates with lymphovascular invasion in squamous cell carcinoma of the penis. Pathology Research and Practice, 2015, 211, 641-645.	1.0	10
36	Analysis of the prognostic relevance of sex-steroid hormonal receptor mRNA expression in muscle-invasive urothelial carcinoma of the urinary bladder. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2019, 474, 209-217.	1.4	10

#	Article	IF	Citations
37	The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder Cancer. Cancer Management and Research, 2021, Volume 13, 6567-6578.	0.9	10
38	Tumor budding correlates with tumor invasiveness and predicts worse survival in pT1 non-muscle-invasive bladder cancer. Scientific Reports, 2021, 11, 17981.	1.6	9
39	Increased Proliferation as Independent Predictor of Disease Recurrence in Initial Stage pTa Urothelial Bladder Cancer. Bladder Cancer, 2017, 3, 173-180.	0.2	7
40	Improved prediction of nephron-sparing surgery versus radical nephrectomy by the optimized R.E.N.A.L. Score in patients undergoing surgery for renal masses. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 249-257.	3.9	7
41	Aquaporin 3 Expression Loss in Urothelial Carcinoma: Association with Tumor Invasion Depth, but not with Grading?. Bladder Cancer, 2017, 3, 31-34.	0.2	6
42	Strong Expression of Cancertestis Antigens CTAG1B and MAGEA3 Is Correlated with Unfavourable Histopathological Features and MAGEA3 Is Associated with Worse Progression-Free Survival in Urothelial Bladder Cancer. Urologia Internationalis, 2019, 102, 77-82.	0.6	6
43	Characterization of PD-1 and PD-L1 Expression in Papillary Renal Cell Carcinoma: Results of a Large Multicenter Study. Clinical Genitourinary Cancer, 2021, 19, 53-59.e1.	0.9	6
44	Prognostic and Predictive Value of Fibroblast Growth Factor Receptor Alterations in High-grade Non–muscle-invasive Bladder Cancer Treated with and Without Bacillus Calmette-Guérin Immunotherapy. European Urology, 2022, 81, 606-614.	0.9	6
45	Loss of CHEK2 Predicts Progression in Stage pT1 Non-Muscle-Invasive Bladder Cancer (NMIBC). Pathology and Oncology Research, 2020, 26, 1625-1632.	0.9	4
46	Impact of E-Cadherin and β-Catenin as Prognostic Factor in Renal Cell Carcinoma with Tumor Thrombus of the Vena Cava. Urologia Internationalis, 2019, 102, 413-420.	0.6	3
47	cMET: a prognostic marker in papillary renal cell carcinoma?. Human Pathology, 2022, 121, 1-10.	1.1	3
48	BioScore (B7-H1, survivin, and Ki-67) does not predict cancer-specific mortality in surgically treated patients with renal cell carcinoma: An external validation study. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 510-518.	0.8	2
49	Stage T1 bladder cancer: historic background and latest tracks for its demystification. Translational Andrology and Urology, 2018, 7, 760-763.	0.6	1
50	Expression of Low Affinity Nerve Growth Factor Receptor p75 in Classic Bladder Exstrophy. Frontiers in Pediatrics, 2021, 9, 634343.	0.9	1
51	Serine threonine kinase 15 amplification in normal urothelium of cystectomy specimens is no prognostic factor in urothelial carcinoma of the bladder. Pathology Research and Practice, 2011, 207, 161-163.	1.0	0
52	Predictive Value of Positive Surgical Margins after Radical Prostatectomy for Lymph Node Metastasis in Locally Advanced Prostate Carcinoma. Advances in Urology, 2012, 2012, 1-3.	0.6	0
53	Impact of Male Patient Information on Quality of Urine Examination (PIQUE Study). Urologia Internationalis, 2021, , , 1-5.	0.6	0